Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

Literature reviews are a crucial part of life sciences research. They can reveal gaps in the existing research, provide information on unmet needs, and inform new market strategies. Even regulatory bodies rely heavily on literature reviews to help shape clinical guidelines and evaluate the effectiveness of treatments through statistical processes such as network meta-analysis. But there’s a catch ...

Randomized clinical trials are the gold standard of evidence to support decision-making and the development of clinical practice recommendations. Yet, by design, they typically assess a drug’s safety and efficacy on a narrow patient population with pre-defined treatment strategies and over a short time horizon. Real-world data (RWD)-based simulations allow us to extend the insights already ...

The 21st century has brought about significant technological advancement, allowing the collection of new types of data from the real world on an unprecedented scale. The healthcare industry will benefit immensely from this abundance of patient data from electronic health records (EHRs), patient-reported outcomes (PROs), laboratory, demographic, social media, digital, and even climate data. While ...

Real world evidence (RWE) has traditionally been leveraged to inform predominantly product development decisions, payer contracts, and health economic and outcome research (HEOR) studies. There is now an increased emphasis on leveraging RWE across a broader range of business functions given the industry shift towards specialty drugs and the treatment of rare diseases. Now with more outcomes-based ...

The recent announcement of Biogen’s potential breakthrough in finding a drug that may finally deliver benefits to Alzheimer’s patients represents a milestone in treating this dreadful disease. It also should serve as a reminder and an important lesson to those who wish to undermine this engine of innovation on the incentives needed to bring novel medicines to the marketplace. Unfortunately, a ...

It is widely believed that machine learning and data mining are right on the cusp of becoming among the most important breakthroughs that the healthcare industry has seen in years. While applications of these techniques have already occurred elsewhere in the pharma sector, wide-spread applications in pharmaceutical commercial analytics have come more recently. Pharma companies are now looking to ...

The pharmaceutical industry continues to undergo tremendous changes. The questions for executives are how do these changes affect the direction of investments in new decision science technologies and whether there should be focus on certain areas of expertise that are felt to offer a competitive advantage for the company? These choices in the direction of investments are embodied in the title of ...

The biopharmaceutical industry is undergoing significant changes. Most importantly, there is a shift toward greater company R&D focus on and launching of specialty medicines that use new scientific drug delivery systems, e.g., large molecules as opposed to traditional small molecule drugs, catering to smaller patient populations. While this shift solves some problems pharma has been facing, ...

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of intangible assets like intellectual property (IP) will be fundamental to future biopharmaceutical financial success. The global nature and internal structure of biopharmaceutical multinational corporations (MNCs) means ...